Novo Nordisk Faces Generic Pressure as Chile Spends Nearly US$100M a Year on Weight-Loss Drugs
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo Nordisk’s retail dominance under direct competitive pressure.
DRUG PRICING · GENERIC DRUG ENTRY · SEPTEMBER 28, 2026 · CHILE
At nearly US$100 million a year in spending, according to La Tercera, Chile’s market for weight-loss treatments led by semaglutide has grown large enough to attract a wave of generic challengers — and to put Novo Nordisk’s retail pricing under pressure that the company’s oral pipeline may not fully offset.
According to IQVIA data reported by La Tercera, cumulative semaglutide sales in Chile reached US$415 million at retail prices between July 2021 and July 2026, with 735,952 units sold annually in the most recent 12-month period. Year-on-year sales growth ran at 54% in the year to June 2026, per the same source. In Chile, Novo Nordisk’s injectable glucagon-like peptide-1 (GLP-1) receptor agonists — sold under the Ozempic and Wegovy brands — have operated without generic competition.
That position is now contested. Laboratorio Chile, a subsidiary of Israel’s Teva, has submitted Selfix — a semaglutide generic — for regulatory review at the Instituto de Salud Pública (ISP), Chile’s national medicines regulator, according to La Tercera and Nuevo Poder. Selfix is one of seven generic semaglutide applications under ISP review, according to the regulator. The ISP classifies these generics as chemically synthesised, unlike the biologically derived Ozempic, and says that requires a full review.
The India precedent and what it implies for pricing
The international context sharpens the stakes. In India, where Novo Nordisk’s semaglutide patent expired in March 2026, three manufacturers — Sun Pharma, Dr. Reddy’s and Glenmark — received approval from the Drug Controller General of India (DCGI), India’s medicines regulator, and began selling generic versions within days of the patent lapse, according to Cinco Días. Dr. Reddy’s launched Obeda at approximately 4,200 rupees (around 39 euros) per month; Glenmark’s Glipiq was priced between 325 and 440 rupees per week, per Cinco Días. By comparison, the list price for Ozempic in the United States for an uninsured patient runs between US$900 and US$1,100 per month, according to Cinco Días. Cinco Días reported that the Indian generic entry is expected to reduce treatment costs by up to 80%.
Chile’s patent and regulatory environment differs from India’s, and the ISP said in August that all seven applications would go in September before its new-products commission, which proposes approval or rejection; as of 19 September, La Tercera reported Laboratorio Chile was still awaiting approval for Selfix. The India case is therefore an international reference point, not a direct forecast — but it establishes that rapid multi-entrant generic competition in semaglutide markets can compress prices sharply once regulatory clearance is granted.
Domenico Forte, chief executive of Novo Nordisk in Chile, told La Tercera the evaluation of the Wegovy launch ‘is positive’ and that Chile is among the first countries in the region to have the drug. The company’s broader posture in 2026 has been to compete on volume and oral formulations: Novo Nordisk’s chief executive Mike Doustdar stated in the company’s May 2026 first-quarter results announcement that ‘the strong Wegovy performance, combined with continued growth in International Operations, has led us to raise our 2026 guidance for both adjusted sales and adjusted operating profit’ — and on 4 August 2026 the company raised its guidance again, to adjusted sales growth of 0% to -6% at constant exchange rates.
A market the public system does not yet cover
The Chilean government’s Garantías Explícitas en Salud (GES) programme — the statutory benefit package that covers 90 health conditions under the Decreto GES 2025-2028 announced by President Gabriel Boric and Health Minister Ximena Aguilera in December 2025 — does not list obesity among its guaranteed conditions. The DESAL (Departamento de Economía de la Salud, Chile’s Ministry of Health health-economics unit) analysis of the Ley N°21.198 (Ley Cenabast) — which allows the Central de Abastecimiento del Sistema Nacional de Servicios de Salud (Cenabast), Chile’s public procurement agency, to intermediate drug purchases for private pharmacies — covers the 2021–2024 period and evaluates price and savings impacts across the Cenabast portfolio.
Laboratorio Chile general manager Juan Meli told La Tercera that there is currently no broad coverage for this type of treatment. A DESAL report published in December 2021 noted that Chile’s pharmaceutical market represented 1.6% of gross domestic product (GDP) in 2020, with average annual growth of 10% between 2011 and 2020.
The principal friction in the generic entry scenario is regulatory throughput, not commercial intent. ISP review timelines for new generic applications vary, and a cleared registration does not translate immediately into stocked pharmacy shelves or procurement-list inclusion. With seven applications already under review, Chile could see multi-entrant competition once the first synthetic semaglutide is cleared; the ISP said in May that the remaining applications would then advance expeditiously.
Analyst estimates for the global obesity-drug market were revised downward in early 2026. Jefferies cut its 2030 weight-loss market projection by 20% to a maximum of US$80 billion, from a 2023 estimate of more than US$100 billion, according to Reuters; Jefferies analyst Michael Leuchten told Reuters: ‘That $150 billion pie is gone, even if you’re very bullish on volumes.’ These revisions reflect the combined effect of price competition in the United States and the accelerating generic entry in markets where patents have lapsed.
What to Watch
ISP regulatory decision on Selfix (Laboratorio Chile / Teva): the timing and outcome will determine when a lower-priced semaglutide reaches Chilean pharmacies.
How many of the seven semaglutide generic applications under ISP review are approved, and in what order.
Any Cenabast intermediation decision covering semaglutide, which would extend price pressure into the public-adjacent retail channel and expand access beyond current out-of-pocket payers.
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
You're in. The next Brief lands in your inbox.
The deeper structural point is that Chile’s semaglutide market has grown large enough — US$415 million cumulatively, nearly US$100 million a year by La Tercera’s estimate — to make generic entry commercially viable, independent of what happens in Europe, where Cinco Días reports semaglutide patent protection runs until 2031. The competitive clock in Chile is set by the ISP’s review calendar, not by Novo Nordisk’s global patent strategy.
Chile Semaglutide Market in Numbers
US$415M
Cumulative semaglutide sales at retail prices, July 2021 – July 2026
IQVIA, via La Tercera
735,952
Units sold in the moving annual total (MAT) to 2026
IQVIA, via La Tercera
+54%
Sales growth, July 2025 – June 2026
IQVIA, via La Tercera
7
Generic semaglutide applications under ISP review
Instituto de Salud Pública (ISP)
Sources: La Tercera (IQVIA data), September 2026; Instituto de Salud Pública (ISP), August 2026.
Why this is relevant
Patients
Obesity is not among the 90 GES guaranteed conditions, and Laboratorio Chile says there is currently no broad coverage for this type of treatment; ISP approval of generic semaglutide, including Selfix, could reduce treatment costs, though the timeline for regulatory clearance and pharmacy availability remains uncertain.
Industry
Seven chemically synthesised semaglutide applications are before the ISP, including Selfix from Teva subsidiary Laboratorio Chile, at a moment when cumulative semaglutide sales have reached US$415 million and year-on-year growth stands at 54%, making the market commercially significant enough to sustain competitive entry and potential price compression.
Payers
Obesity is not a GES guaranteed condition; Laboratorio Chile estimates that a generic costing US$1,283 a year, against US$3,206 for the brand, could save the health system US$225 million — a company projection that assumes ISP approval.
Caregivers
With Ozempic retailing at between 165,000 and more than 300,000 Chilean pesos per pen, according to La Tercera, families supporting members with obesity face sustained financial pressure until generic entry, if approved by the ISP, translates into lower pharmacy shelf prices — a lag that depends on ISP throughput and pharmacy uptake.
A CVS Health white paper using Aetna claims data finds GLP-1s offset their full cost to plan sponsors only at $350 per month — well below current employer prices of $617–$766 monthly.
Pelacarsen reduced lipoprotein(a) (Lp(a)) by 78% in a Phase III trial of more than 8,300 adults yet produced no reduction in major adverse cardiovascular events, raising questions about whether lowering Lp(a) reduces them.
An international trial of 702 randomized adults found left bundle branch pacing (LBBP) lowered the hazard of death, heart failure hospitalization or pacing-induced cardiomyopathy by 59% (hazard ratio 0.41) versus right ventricular pacing (RVP); the …
New Institute for Health Metrics and Evaluation estimates show global health financing dropped 5% in 2026, following a 12% cut in 2025, as the UK posted the largest absolute reduction and low-income countries face the …